Needelman Asset Management’s Gilead Sciences GILD Stock Holding History

Needelman Asset Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-22,015	Closed	-$1.56M	–	14
2018 Q2	$1.56M	Sell	22,015 -115	-0.5%	-$8.12K	3.39%	6
2018 Q1	$1.67M	Buy	22,130 +6,965	+46%	+$554K	3.6%	6
2017 Q4	$1.09M	Sell	15,165 -325	-2%	-$24.7K	2.71%	20
2017 Q3	$1.25M	Buy	+15,490	New	+$1.18M	3.08%	12

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Needelman Asset Management's GILD Position: Q3 2018 in Review

Needelman Asset Management sold out of Gilead Sciences (GILD) in Q3 2018, closing a stake of 22,015 shares — an estimated $1.56M sold.

Needelman Asset Management first reported a position in GILD in Q3 2017 and held it in 4 quarters. The position peaked at $1.67M in Q1 2018. 1,528 funds tracked by Wall St. Rank hold GILD as of Q3 2018.

Needelman Asset Management reported no remaining Gilead Sciences position as of Q3 2018 after selling out during the quarter.
Needelman Asset Management sold 22,015 Gilead Sciences shares in Q3 2018, an estimated $1.56M.
Needelman Asset Management first reported a position in Gilead Sciences in Q3 2017 and held it in 4 quarters.
Needelman Asset Management's Gilead Sciences position peaked at $1.67M in Q1 2018.
1,528 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2018.

Based on Needelman Asset Management's 13F filing for Q3 2018.